Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005-2015 show improved survival over time.
Finland
chemoimmunotherapy
chronic lymphocytic leukaemia
epidemiology
registry
survival
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
18
03
2019
revised:
29
05
2019
accepted:
03
06
2019
pubmed:
19
6
2019
medline:
25
1
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
We aimed to describe treatment patterns of chronic lymphocytic leukaemia (CLL) patients in routine practice settings, compare overall survival and time-to-next-treatment among patients treated in different time periods (2005-2008, 2009-2013, 2014-2015), and explore associated factors. This retrospective cohort study included adult CLL patients from the Finnish Hematology Registry. In total, 124 and 64 CLL patients received first- and second-line treatments, respectively. The use of first- and second-line treatments with bendamustine-rituximab (BR) increased, while chlorambucil-based treatments decreased over time. Patients treated in more recent years showed a trend towards longer first- and second-line survival. A trend towards inferior overall survival was detected in first- and second-line treatment with B/BR. First-line time-to-next-treatment was longer for patients treated in the later years towards 2015, while second-line time-to-next-treatment did not improve over time. This study identified that improved treatment outcomes over time were likely influenced by patient characteristics and treatments, but also through other factors unexplored in this study. Hence, further research on the factors influencing patients' survival over time is needed. In particular, research on using B/BR in clinical practice is warranted.
Identifiants
pubmed: 31210368
doi: 10.1111/ejh.13273
pmc: PMC6851967
doi:
Types de publication
Historical Article
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190-199Informations de copyright
© 2019 The Authors. European Journal of Haematology Published by John Wiley & Sons Ltd.
Références
Cancer Med. 2016 Dec;5(12):3588-3595
pubmed: 27925456
PLoS One. 2013 Apr 24;8(4):e62930
pubmed: 23638168
Haematologica. 2014 Jun;99(6):1095-100
pubmed: 24584349
J Natl Compr Canc Netw. 2019 Jan;17(1):12-20
pubmed: 30659125
Haematologica. 2018 Jul;103(7):1209-1217
pubmed: 29674504
J Hematol Oncol. 2016 Mar 22;9:28
pubmed: 27000264
Haematologica. 2009 Sep;94(9):1259-65
pubmed: 19734417
Lancet Haematol. 2018 Jan;5(1):e14-e24
pubmed: 29304322
Ann Hematol. 2011 Oct;90(10):1123-9
pubmed: 21614458
Blood Cancer J. 2016 Nov 11;6(11):e499
pubmed: 27834937
Leuk Lymphoma. 2017 May;58(5):1219-1223
pubmed: 27894205
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e11-e25
pubmed: 28802891
Lancet Oncol. 2016 Feb;17(2):200-211
pubmed: 26655421
Am J Hematol. 2017 Sep;92(9):946-965
pubmed: 28782884
Leukemia. 2019 Apr;33(4):969-980
pubmed: 30315239
Nat Rev Clin Oncol. 2018 Aug;15(8):510-527
pubmed: 29777163
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Br J Haematol. 2012 Dec;159(5):541-64
pubmed: 23057493
Eur J Haematol. 2018 Sep;101(3):399-406
pubmed: 29949186
Blood. 2008 May 15;111(10):4916-21
pubmed: 18309034
Leuk Res. 2017 Apr;55:79-90
pubmed: 28157628
Lancet Oncol. 2016 Jul;17(7):928-942
pubmed: 27216274
J Clin Oncol. 2011 Sep 10;29(26):3559-66
pubmed: 21844497
Ann Oncol. 2015 Sep;26 Suppl 5:v78-84
pubmed: 26314781
Eur J Haematol. 2019 Sep;103(3):190-199
pubmed: 31210368
Hematol Oncol. 2015 Mar;33(1):15-22
pubmed: 24733536